Demographics, previous and concomitant therapies, and disease status
| Interval prolongation (n=27) | Continuation (n=27) | |||
| Baseline | Week 28 | Baseline | Week 28 | |
| Demographics | ||||
| Age, mean±SD years | 60 ± 10 | – | 58 ± 13 | – |
| Female, n (%) | 25 (93) | – | 26 (96) | – |
| BMI, mean±SD | 24.8 ± 5.0 | – | 23.8 ± 4.3 | – |
| Previous therapies | ||||
| Prior DMARDs, median (IQR) | 3 (2–3) | – | 2 (2–3) | – |
| Prior biologic, n (%) | 4 (15) | – | 3 (11) | – |
| Adalimumab treatment, median (IQR) years | 6.0 (2.9–8.0) | – | 5.5 (1.8–8.3) | – |
| Concomitant therapies | ||||
| MTX use, n (%) | 26 (96) | 25 (93) | 25 (93) | 25 (93) |
| MTX dosage, median (IQR) mg/week | 20 (15–21) | 15 (11–20) | 15 (10–20) | 15 (10–20) |
| Prednisone use, n (%) | 4 (15) | 4 (15) | 1 (4) | 0 (0) |
| Disease status | ||||
| Disease duration, median (IQR) years | 11 (8–18) | – | 11 (6–19) | – |
| ACPA positive, n (%) | 18 (67) | – | 21 (78) | – |
| IgM-RF positive, n (%) | 20 (74) | – | 20 (74) | – |
| Erosive disease, n (%) | 17 (63) | – | 17 (63) | – |
| Primary outcome: DAS28-ESR, mean±SD | 2.0 ± 0.8 | 1.9 ± 0.7 | 1.6 ± 0.7 | 2.0 ± 0.9 |
| Patient’s pain, median (IQR) mm | 15 (3–38) | 17 (4–34) | 10 (6–21) | 13 (9–22) |
| Patient’s global, median (IQR) mm | 15 (3–37) | 16 (4–37) | 15 (11–25) | 19 (8–35) |
| Physician’s global, median (IQR) mm | 4 (3–14) | 9 (2–21) | 12 (5–17) | 15 (7–26) |
| Swollen joint count, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Tender joint count, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| ESR, median (IQR) mm/hour | 9 (5–18) | 7 (5–18) | 5 (3–11) | 7 (4–14) |
| CRP, median (IQR) mg/L | 1 (1–3) | 1 (1–2) | 1 (1–3) | 1 (1–2) |
| HAQ, median (IQR) | 0.4 (0.1–1.0) | 0.5 (0.1–0.8) | 0.5 (0.1–1.3) | 0.6 (0.1–1.1) |
ACPA, anticitrullinated protein antibody; BMI, body mass index; CRP, C-reactive protein; DAS28, 28 joints disease activity score; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IgM-RF, IgM rheumatoid factor; MTX, methotrexate; SD, standard deviation.